Kodiak Sciences Inc - KOD STOCK NEWS

Kodiak Sciences Inc. reported business highlights and financial results for Q2 2023. The Phase 3 studies of tarcocimab in diabetic macular edema (DME) did not meet their primary efficacy endpoints, but the DAYLIGHT study in wet age-related macular degeneration (wet AMD) did. The company has decided to wind down ongoing studies of tarcocimab. Kodiak will advance the KSI-501 clinical program, a first-in-class anti-IL-6 and anti-VEGF bispecific molecule. The company ended Q2 2023 with $378.7 million in cash and cash equivalents.

Kodiak Sciences Inc. announced topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody biopolymer conjugate. The DAYLIGHT study met the primary endpoint of non-inferior visual acuity gains for tarcocimab dosed monthly compared to aflibercept dosed every 8 weeks. The GLEAM and GLIMMER studies did not meet their primary efficacy endpoints. An increase in cataracts was observed in the tarcocimab arms of both studies. Kodiak has decided to discontinue further development of tarcocimab.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company, has announced multiple scientific presentations on its clinical pipeline at the ARVO 2023 Annual Meeting in New Orleans from April 23-27, 2023. Key presentations will include data on tarcocimab tedromer (KSI-301) and KSI-501, focusing on their effectiveness in treating retinal diseases. Victor Perlroth, CEO of Kodiak, emphasized their commitment to advancing therapeutics targeting high-prevalence retinal diseases. The company is conducting Phase 3 studies for tarcocimab and a Phase 1 study for KSI-501. The results from these studies are pivotal, with topline data expected in 3Q2023, potentially leading to a single Biologics Licensing Application for multiple indications.

Kodiak Sciences Inc. (Nasdaq: KOD) announced the initiation of a Phase 1 clinical study for KSI-501, an investigational bispecific antibody biopolymer conjugate, designed to treat diabetic macular edema (DME). The study, conducted in the USA, aims to evaluate the safety and maximum tolerated dose of KSI-501. This product targets both vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6), addressing inflammatory components in retinal diseases. The ABC Platform utilized for KSI-501 may provide unique therapeutic benefits, including extended durability. Kodiak's ongoing research aims to broaden treatment options in retinal diseases, anticipating future insights from the study.

Kodiak Sciences Inc. (KOD) reported Q4 2022 results, highlighting a net loss of $70.4 million, or $1.35 per share, an improvement from $93.2 million, or $1.79 per share, in Q4 2021. R&D expenses decreased to $56 million from $75.6 million, attributed to the maturation of the tarcocimab program. The company holds $478.9 million in cash and equivalents. Key upcoming events include topline data from four Phase 3 studies set for Q3 2023. Kodiak is also advancing KSI-501, a bispecific antibody, expected to enter clinical testing. The firm aims to enhance its market position in retinal diseases with innovative therapies.

Kodiak Sciences Inc. (Nasdaq: KOD) announced a presentation scheduled for February 11, 2023, at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting, focusing on clinical data for its investigational therapy KSI-301 (tarcocimab tedromer) and updates on its Antibody Biopolymer Conjugate (ABC) development programs. CEO Victor Perlroth highlighted the progress with KSI-301, anticipating four Phase 3 clinical study readouts in Q3 2023. Additionally, the company has successfully opened an Investigational New Drug (IND) application for KSI-501, a bispecific therapy aimed at retinal diseases, with a Phase 1 study set to begin shortly.

Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:00 a.m. PT in San Francisco, CA. The event will feature a presentation by management, with a live webcast available on Kodiak's website. The company focuses on developing therapeutics for retinal diseases, leveraging its proprietary ABC Platform™. Kodiak's lead candidate, tarcocimab tedromer, aims to treat conditions like wet age-related macular degeneration and diabetic eye diseases.